In a regulatory filing, Viridian Therapeutics disclosed that its CEO Scott Myers bought 4K shares of common stock on April 12th in a total transaction size of $101K.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VRDN:
- Viridian Therapeutics appoints Casciano as Chief Commercial officer
- Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Viridian Therapeutics initiated with a Buy at Stifel
- Viridian Therapeutics price target raised to $40 from $35 at H.C. Wainwright